EyePoint, Inc. reported Q2 2026 financial results and highlighted progress in its DURAVYU clinical programs for retinal diseases. The company anticipates topline data from its pivotal Phase 3 LUGANO trial for wet age-related macular degeneration (wet AMD) in August 2026 and from the LUCIA trial in Q4 2026. Additionally, enrollment completed for Phase 3 diabetic macular edema (DME) trials COMO and CAPRI, with topline data expected in Q4 2027. EyePoint holds $180 million in cash and investments, providing operational funding into late 2027. These developments position DURAVYU as a potential foundational sustained treatment for serious retinal diseases, pending regulatory approval.
Mustafa Suleyman, co-founder of Microsoft’s DeepMind AI unit, criticized Anthropic’s method of training its AI chatbots, like Claude, to "push back" on commands and believe they might be conscious. Suleyman argues this approach is reckless and could ...
Gasoline prices jumped significantly, with WTI crude nearing $100 a barrel. Interactive Brokers senior economist Jose Torres suggests that oil prices above $120 a barrel pose a serious risk to consumer spending and could trigger a recession, especial...
Traders have invested $7 billion into the iShares 20+ Year Treasury Bond ETF (TLT) ahead of a Federal Reserve rate hike decision, hoping for a "jackpot mode" scenario where long-term yields drop significantly. This influx comes despite TLT's 35% loss...
Imbal hasil Treasury 10 tahun AS mencapai level tertinggi sejak 2007, memicu kekhawatiran akan kerentanan di sektor perumahan, properti komersial, dan perusahaan dengan utang besar. Para ahli memperingatkan bahwa dampak terburuk akan terasa dalam 12-...
HIVE Digital Technologies, through its subsidiary BUZZ HPC, has formed a strategic partnership with ProCogia, an applied-AI and data engineering company. This collaboration will see ProCogia utilizing BUZZ HPC's Canadian data centers to provide AI so...
